We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Sales of Roche's antiviral Tamiflu are on target to top the $1 billion mark this year, but the company has announced demand from government stockpiling initiatives is winding down.